Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
Amyloidosis
Cardiopulmonary exercise test
Circulatory power
Peak oxygen consumption
Prognosis
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
revised:
20
08
2020
received:
09
05
2020
accepted:
26
09
2020
pubmed:
3
10
2020
medline:
6
7
2021
entrez:
2
10
2020
Statut:
ppublish
Résumé
In amyloid patients, cardiac involvement dramatically worsens functional capacity and prognosis. We sought to study how the cardiopulmonary exercise test (CPET) could help in functional assessment and risk stratification of patients with cardiac amyloidosis (CA). We carried out a multicentre study including patients with light chain (AL) or transthyretin (TTR) CA. All patients underwent exhaustive examination including CPET and follow-up. The primary prognostic endpoint was the occurrence of death or heart failure hospitalization. Overall, 150 patients were included (91 AL and 59 TTR CA). Median age, systolic blood pressure, N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin T were 70 (64-78) years, 121 [interquartile range (IQR) 109-139] mmHg, 2806 (IQR 1218-4638) ng/L and 64 (IQR 33-120) ng/L, respectively. New York Heart Association classes were I-II in 64%. Median peak oxygen consumption (VO In CA, CPET is helpful in assessing functional capacity, circulatory and chronotropic responses as well as the prognosis of patients along with cardiac biomarkers.
Substances chimiques
Biomarkers
0
Peptide Fragments
0
Troponin T
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
231-239Informations de copyright
© 2020 European Society of Cardiology.
Références
Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733-2779.
Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016;387:2641-2654.
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:2872-2891.
Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017;135:1357-1377.
Nicol M, Baudet M, Cescau A, Harel S, Royer B, Sarda-Mantel L, Cohen-Solal A, Arnulf B, Logeart D. Prognostic value of iodine-123-metaiodobenzylguanidine scintigraphy in light-chain amyloidosis. Circ Cardiovasc Imaging 2019;12:e009465.
Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS, Liao R. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008-1010.
Paolillo S, Veglia F, Salvioni E, Corrà U, Piepoli M, Lagioia R, Limongelli G, Sinagra G, Cattadori G, Scardovi AB, Metra M, Senni M, Bonomi A, Scrutinio D, Raimondo R, Emdin M, Magrì D, Parati G, Re F, Cicoira M, Minà C, Correale M, Frigerio M, Bussotti M, Battaia E, Guazzi M, Badagliacca R, di Lenarda A, Maggioni A, Passino C, Sciomer S, Pacileo G, Mapelli M, Vignati C, Clemenza F, Binno S, Lombardi C, Filardi PP, Agostoni P; MECKI Score Research Group. Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. Eur J Heart Fail 2019;21:208-217.
Trikas A, Rallidis L, Hawkins P, Oakley CM, Nihoyannopoulos P. Comparison of usefulness between exercise capacity and echocardiographic indexes of left ventricular function in cardiac amyloidosis. Am J Cardiol 1999;84:1049-1054.
Hein S, Aus Dem Siepen F, Bauer R, Katus HA, Kristen AV. Peak V'O2 is an independent predictor of survival in patients with cardiac amyloidosis. Amyloid 2018;25:167-173.
Yunis A, Doros G, Luptak I, Connors LH, Sam F. Use of ventilatory efficiency slope as a marker for increased mortality in wild-type transthyretin cardiac amyloidosis. Am J Cardiol 2019;124:122-130.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463.
Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010;3:155-164.
Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018;39:2799-2806.
Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020;22:39-53.
Nicol M, Baudet M, Brun S, Harel S, Royer B, Vignon M, Lairez O, Lavergne D, Jaccard A, Attias D, Macron L, Gayat E, Cohen-Solal A, Arnulf B, Logeart D. Diagnostic score of cardiac involvement in AL amyloidosis. Eur Heart J Cardiovasc Imaging 2020;21:542-548.
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-995.
Wasserman K. Principles of Exercise Testing and Interpretation: Including Pathophysiology and Clinical Applications. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
Tabet JY, Beauvais F, Thabut G, Tartière JM, Logeart D, Cohen-Solal A. A critical appraisal of the prognostic value of the VE/VCO2 slope in chronic heart failure. Eur J Cardiovasc Prev Rehabil 2003;10:267-272.
Guazzi M, Cahalin LP, Arena R. Cardiopulmonary exercise testing as a diagnostic tool for the detection of left-sided pulmonary hypertension in heart failure. J Card Fail 2013;19:461-467.
Brawner CA, Ehrman JK, Schairer JR, Cao JJ, Keteyian SJ. Predicting maximum heart rate among patients with coronary heart disease receiving beta-adrenergic blockade therapy. Am Heart J 2004;148:910-914.
Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172; discussion 207-212.
Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med 2017;36:4391-4400.
Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016;68:1014-1020.
Russo C, Green P, Maurer M. The prognostic significance of central hemodynamics in patients with cardiac amyloidosis. Amyloid 2013;20:199-203.
Clemmensen TS, Mølgaard H, Sörensen J, Eiskjaer H, Andersen NF, Mellemkjaer S, Andersen MJ, Tolbod LP, Harms HJ, Poulsen SH. Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis. Eur J Heart Fail 2017;19:1457-1465.
Guazzi M. Exercise VE/VCO2 slope: an endurance marker of prognosis also in patients with HFpEF and pulmonary hypertension, at least! J Card Fail 2017;23:783-785.
Brubaker PH, Kitzman DW. Chronotropic incompetence: causes, consequences, and management. Circulation 2011;123:1010-1020.
Chacko L, Martone R, Bandera F, Lane T, Martinez-Naharro A, Boldrini M, Rezk T, Whelan C, Quarta C, Rowczenio D, Gilbertson JA, Wongwarawipat T, Lachmann H, Wechalekar A, Sachchithanantham S, Mahmood S, Marcucci R, Knight D, Hutt D, Moon J, Petrie A, Cappelli F, Guazzi M, Hawkins PN, Gillmore JD, Fontana M. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J 2020;41:1439-1447.